Top 5 Drug Type | Count |
---|---|
Biosimilar | 5 |
Monoclonal antibody | 4 |
Small molecule drug | 3 |
Unknown | 2 |
Colony-stimulating factors | 1 |
Target |
Mechanism RdRp inhibitors [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. GB |
First Approval Date14 Nov 2021 |
Target |
Mechanism Proton pump inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. DE |
First Approval Date01 Jan 1994 |
Target |
Mechanism ACE inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date28 Jan 1991 |
Start Date30 Nov 2023 |
Sponsor / Collaborator |
Start Date28 Feb 2023 |
Sponsor / Collaborator |
Start Date30 May 2022 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Molnupiravir ( RdRp ) | COVID-19 More | Approved |
Ramipril ( ACE ) | Hypertension More | Approved |
Rituximab biosimilar (Hetero Drugs) ( CD20 ) | Non-Hodgkin Lymphoma More | Approved |
Darbepoetin alfa biosimilar(Hetero Drugs Ltd.) ( EPO receptor ) | Anemia More | Approved |
Bevacizumab biosimilar(Hetero Drugs Ltd.) ( VEGF-A ) | Colorectal Cancer More | Approved |